EGFR and non-small cell lung carcinoma: Bevacizumab, a humanized monoclonal antibody targeting VEGF, has been shown to significantly prolong progression-free survival (PFS) in advanced NSCLC when administered in combination with standard first-line platinum-based chemotherapies or EGFR TKIs [26].